University of California San Diego Moores Cancer Center (Adults Only)
Welcome,         Profile    Billing    Logout  
 10 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ekong, Udeme
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
EMBARK, NCT04524390 / 2020-000974-22: Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Completed
2
75
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625, Placebo
Mirum Pharmaceuticals, Inc.
Biliary Atresia
11/23
02/24
Mulroney, Carolyn M
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
Taplitz, Randy
NCI-2020-08335, NCT04639466: A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

Active, not recruiting
1/2
119
US
Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
GeoVax, Inc., National Cancer Institute (NCI), City of Hope Medical Center
COVID-19 Infection
03/25
06/25

Download Options